A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

进一步回顾2024年复旦大学附属肿瘤医院乳腺癌诊疗情况，截止到11月底，总乳腺癌手术例数9764例，截止到12月底则10690例，70岁以上的患者800余例，1400余例低-中级别导管原位癌。近7000例患者接受了前哨淋巴结活检，其中前哨淋巴结1到2 ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

该研究的突破性发现不仅为ER+/HER2−乳腺癌患者提供了全新的治疗选择，还为未来的个体化治疗开辟了新的方向。通过将免疫 ...

Three-fourths of patients with unresectable gastroesophageal cancer converted to resectable and had clear margins after ...

Adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.

In recent years, quantitative real-time PCR tests have been extensively developed in clinical microbiology laboratories for routine diagnosis of infectious diseases, particularly bacterial diseases.

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression, based on DESTINY-Breast06 trial results. Enhertu showed a 36% reduction in ...

In HER2+ breast cancer, achieving pCR has also been shown to correlate with better survival outcomes. A systematic review confirmed that patients who achieve pCR after neoadjuvant therapy have ...

冬至阳生，岁回律转，在此新旧交替之际，中国医学论坛报特别策划 “名家领航，年度盘点丨2024年度肿瘤领域进展权威解读”活动，诚邀肿瘤各领域专家回顾解读2024年度肿瘤领域重磅研究，传播前沿进展，引领学术创新。 2025年1月3-5日，“2025乳腺癌北方沙龙· ...

Australian researchers achieve a breakthrough in improving breast cancer cure rates, offering new hope for patients worldwide ...